Abstract
Interferons establish innate antiviral immunity. Two recent papers in JEM by Lopez et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20211211) and Cheemarla et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210583) show that an appropriate supply of antiviral interferon enables epithelial cells of the nasopharyngeal mucosa to inhibit SARS-CoV-2 growth and that interferon-induced mucosal genes serve as biomarkers of infection.
All Keywords
【초록키워드】 Biomarker, Biomarkers, Antiviral, Infection, interferons, interferon, nasopharyngeal, innate antiviral immunity, epithelial cells, mucosal, epithelial cell, mucosa, growth, Exp, inhibit SARS-CoV-2, 【제목키워드】 the SARS-CoV-2,
【초록키워드】 Biomarker, Biomarkers, Antiviral, Infection, interferons, interferon, nasopharyngeal, innate antiviral immunity, epithelial cells, mucosal, epithelial cell, mucosa, growth, Exp, inhibit SARS-CoV-2, 【제목키워드】 the SARS-CoV-2,
{{{ 추상적인 }}}
인터페론은 선천적인 항바이러스 면역을 확립합니다. Lopez et al.의 JEM의 두 최근 논문. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20211211) 및 Cheemarla et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210583) 항바이러스 인터페론의 적절한 공급은 비인두 점막의 상피 세포가 SARS-CoV-2 성장을 억제하고 인터페론- 유도된 점막 유전자는 감염의 바이오마커 역할을 합니다.